Logo image of PBLA

PANBELA THERAPEUTICS INC (PBLA) Stock Fundamental Analysis

USA - NASDAQ:PBLA - US69833W4042 - Common Stock

1.11 USD
-0.12 (-9.76%)
Last: 3/6/2024, 8:15:57 PM
1.04 USD
-0.07 (-6.31%)
After Hours: 3/6/2024, 8:15:57 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to PBLA. PBLA was compared to 541 industry peers in the Biotechnology industry. PBLA has a bad profitability rating. Also its financial health evaluation is rather negative. PBLA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PBLA had negative earnings in the past year.
In the past year PBLA has reported a negative cash flow from operations.
In the past 5 years PBLA always reported negative net income.
In the past 5 years PBLA always reported negative operating cash flow.
PBLA Yearly Net Income VS EBIT VS OCF VS FCFPBLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

PBLA has a worse Return On Assets (-221.35%) than 92.42% of its industry peers.
Industry RankSector Rank
ROA -221.35%
ROE N/A
ROIC N/A
ROA(3y)-276.27%
ROA(5y)-267.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PBLA Yearly ROA, ROE, ROICPBLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 1K -1K -2K

1.3 Margins

PBLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PBLA Yearly Profit, Operating, Gross MarginsPBLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for PBLA has been increased compared to 1 year ago.
PBLA has a worse debt/assets ratio than last year.
PBLA Yearly Shares OutstandingPBLA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5K 10K 15K 20K 25K
PBLA Yearly Total Debt VS Total AssetsPBLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

2.2 Solvency

PBLA has an Altman-Z score of -22.59. This is a bad value and indicates that PBLA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -22.59, PBLA is not doing good in the industry: 89.56% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -22.59
ROIC/WACCN/A
WACCN/A
PBLA Yearly LT Debt VS Equity VS FCFPBLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 5M -5M 10M -10M -15M

2.3 Liquidity

A Current Ratio of 0.21 indicates that PBLA may have some problems paying its short term obligations.
PBLA has a Current ratio of 0.21. This is amonst the worse of the industry: PBLA underperforms 97.98% of its industry peers.
PBLA has a Quick Ratio of 0.21. This is a bad value and indicates that PBLA is not financially healthy enough and could expect problems in meeting its short term obligations.
PBLA has a worse Quick ratio (0.21) than 97.81% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
PBLA Yearly Current Assets VS Current LiabilitesPBLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for PBLA have decreased strongly by -67.23% in the last year.
EPS 1Y (TTM)-67.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PBLA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.41%
EPS Next 2Y41.21%
EPS Next 3Y25.88%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PBLA Yearly Revenue VS EstimatesPBLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 200M 400M 600M 800M
PBLA Yearly EPS VS EstimatesPBLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10K -20K -30K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PBLA. In the last year negative earnings were reported.
Also next year PBLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PBLA Price Earnings VS Forward Price EarningsPBLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PBLA Per share dataPBLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1K -2K -3K -4K

4.3 Compensation for Growth

PBLA's earnings are expected to grow with 25.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.21%
EPS Next 3Y25.88%

More info and screens

0

5. Dividend

5.1 Amount

PBLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PANBELA THERAPEUTICS INC

NASDAQ:PBLA (3/6/2024, 8:15:57 PM)

After market: 1.04 -0.07 (-6.31%)

1.11

-0.12 (-9.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-14 2024-03-14/amc
Earnings (Next)05-02 2024-05-02/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners50.67%
Ins Owner Change0%
Market Cap1.41M
Analysts82.5
Price Target418.2 (37575.68%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.88%
Min EPS beat(2)-65.74%
Max EPS beat(2)-28.02%
EPS beat(4)0
Avg EPS beat(4)-40.7%
Min EPS beat(4)-65.74%
Max EPS beat(4)-18.74%
EPS beat(8)1
Avg EPS beat(8)-85.77%
EPS beat(12)3
Avg EPS beat(12)-61.24%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1900%
EPS NQ rev (1m)1.06%
EPS NQ rev (3m)-1878.86%
EPS NY rev (1m)0.84%
EPS NY rev (3m)-1883.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4010.88
EYN/A
EPS(NY)-35.07
Fwd EYN/A
FCF(TTM)-21.39
FCFYN/A
OCF(TTM)-21.39
OCFYN/A
SpS0
BVpS-1.95
TBVpS-1.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -221.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-276.27%
ROA(5y)-267.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -22.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.65%
EPS Next Y96.41%
EPS Next 2Y41.21%
EPS Next 3Y25.88%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.17%
EBIT Next 3Y3.08%
EBIT Next 5Y8.69%
FCF growth 1Y-338.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-338.93%
OCF growth 3YN/A
OCF growth 5YN/A